SUTRO BIOPHARMA, INC. Total Liabilities
SUTRO BIOPHARMA, INC. (STRO) had Total Liabilities of $297.78 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-12
- 2026-06-30: Liabilities $297.78M.
- 2026-03-31: Liabilities $308.88M.
- 2025-12-31: Liabilities $306.28M.
- 2025-09-30: Liabilities $296.93M.
| Period end | Liabilities |
|---|---|
| 2026-06-30 | $297.78M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $308.88M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $306.28M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $296.93M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $294.47M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $347.24M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $342.61M 10-K · filed 2026-03-23 |
| 2024-09-30 | $340.61M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $336.87M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $305.38M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $321.09M 10-K · filed 2025-03-13 |
| 2023-09-30 | $319.39M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $310.18M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $172.60M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $189.90M 10-K · filed 2024-03-25 |
| 2022-09-30 | $170.97M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $176.56M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $83.30M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $88.84M 10-K · filed 2023-03-30 |
| 2021-09-30 | $87.89M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $52.29M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $51.19M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $62.06M 10-K · filed 2022-02-28 |
| 2020-09-30 | $63.12M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $70.78M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $71.79M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $58.58M 10-K · filed 2021-03-18 |
| 2019-09-30 | $61.77M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $69.26M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $71.74M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $91.60M 10-K · filed 2020-03-16 |
| 2018-09-30 | $99.21M 10-Q · filed 2018-11-14 |
| 2017-12-31 | $47.27M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |